Drugs / VORSETUZUMAB MAFODOTIN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01677390 | Aug 2012 → Dec 2013 | renal cell carcinoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01015911 | Nov 2009 → Nov 2011 | non-Hodgkin lymphoma, renal cell carcinoma | Seagen Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VORSETUZUMAB MAFODOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108672 ↗ |
| Known as | SGN-75 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01015911 ↗ |
| Known as | Vorsetuzumab mafodotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108672 ↗ |
| Known as | Vorsetuzumab mafodotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108672 ↗ |
| Route | Intravenous | “SGN-75 was administered intravenously to 58 patients” PMID 25142258 ↗ Aug 2014 |
| Target | CD70 | “CD70-targeted antibody-drug conjugate SGN-75” PMID 25142258 ↗ Aug 2014 |